Concepedia

Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?

Janusz Mezynski, Carmel Pezaro, Diletta Bianchini, Andrea Zivi, Shahneen Sandhu, E. Thompson, John W. Hunt, Elizabeth Sheridan, Bindumalini Rao Baikady, Ajit Sarvadikar,

Annals of Oncology · 2012 · 248 citations · 20 references

DOI

Concepts

References

20

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

, , +12

Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

Ian F. Tannock, Ronald de Wit, William R. Berry et al. · New England Journal of Medicine · 2004 · 5.7K citations

, , +12

Abiraterone and Increased Survival in Metastatic Prostate Cancer

Johann S. de Bono, Christopher J. Logothetis, Arturo Molina et al. · New England Journal of Medicine · 2011 · 4.4K citations · Full text

, , +17

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

Howard I. Scher, Susan Halabi, Ian F. Tannock et al. · Journal of Clinical Oncology · 2008 · 2.2K citations · Full text

, , +17

Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group

Glenn J. Bubley, Michael A. Carducci, William L. Dahut et al. · Journal of Clinical Oncology · 1999 · 984 citations

, , +16